Psychodynamic Psychotherapy for Psychosis

Status Withdrawn

Clinical Trial Summary

The broad goals of our pilot study are to (1) determine whether psychodynamic psychotherapy for psychosis (PPfP), relative to treatment as usual (TaU), can maintain or augment clinical and functional benefits for patients who have achieved initial recovery in our coordinated specialty care (CSC) early psychosis treatment program; (2) to conduct novel empirical study of how various psychodynamic factors may inform candidate selection, mediate therapeutic effects, and influence relational aspects of the therapy; and (3) to conduct a detailed study of how features of therapist and patient speech and behavior influence therapeutic outcomes, therapeutic alliance alliance, and relational process. This registration focuses on the first goal.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04415541
Study type	Interventional
Source	Yale University
Contact
Status	Withdrawn
Phase	N/A
Start date	May 2021
Completion date	August 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05321602` - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder	Phase 1
Terminated	`NCT03230097` - This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year	Phase 2
Completed	`NCT03497663` - VIA Family - Family Based Early Intervention Versus Treatment as Usual	N/A
Active, not recruiting	`NCT05726617` - Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders	N/A
Not yet recruiting	`NCT06005766` - The Efficacy of Metacognitive Skills Training in the Context of Forensic Psychiatric Care	N/A
Not yet recruiting	`NCT03807388` - ReMindCare App for Patients From First Episode of Psychosis Unit.	N/A
Recruiting	`NCT02874573` - Tocilizumab in Schizophrenia	Phase 1
Completed	`NCT02906553` - The Role of Nitric Oxide in Cognition in Schizophrenia	N/A
Terminated	`NCT02584114` - Brain Effects of Memory Training in Early Psychosis	N/A
Terminated	`NCT02841956` - Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement	N/A
Withdrawn	`NCT02213887` - Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications	Phase 4
Completed	`NCT01981356` - Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis	Phase 0
Recruiting	`NCT02009969` - Serial Comparisons of Abdominal and Neurological MRI Scans	N/A
Recruiting	`NCT02848469` - Irish Omega-3 Study	Phase 2
Completed	`NCT02648321` - Motivational Intervention for Physical Activity in Psychosis	N/A
Enrolling by invitation	`NCT00762866` - Psychiatric Genotype/Phenotype Project Repository
Completed	`NCT00484302` - Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis	N/A
Completed	`NCT00844922` - Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)	Phase 2
Completed	`NCT00130923` - Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder	Phase 4
Completed	`NCT00455234` - Rapid Tranquillization Trial: TREC-India II	Phase 3